A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 814907 in Patients With Mild Alzheimer's Disease

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 814907 in Patients With Mild Alzheimer's Disease

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs IONIS MAPTRx (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; First in man
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 17 Apr 2018 According to the Ionis Pharmaceuticals media release, data from this study will be presented at the 2018 American Academy of Neurology Highlight the Broad Potential of Antisense Drugs for Neurological Diseases
    • 20 Jul 2017 Preclinical data along with trial design presented at the Alzheimer's Association International Conference 2017.
    • 19 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top